ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

A Follow-Up Over Time to the Impact of Reactive Anti-HCV and HCV NAT

C. C. Muse, C. A. Hostetler, R. A. Squires, J. P. Orlowski

LifeShare Transplant Donor Services of Oklahoma, Oklahoma City, OK

Meeting: 2020 American Transplant Congress

Abstract number: A-210

Keywords: Allocation, Donation, Hepatitis C, Procurement

Session Information

Session Name: Poster Session A: Non-Organ Specific: Viral Hepatitis

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: A previous review from one U.S. organ procurement organization (OPO) concluded positive HCV test results yielded high rates of authorized/not recovered donors (ANR), low organs transplanted per donor (OTPD) and higher discard rates. The OPO wished to re-evaluate the impact and acceptance of HCV positive donors to see if these factors have changed over time.

*Methods: An analysis between two 15-month time frames of recovered organ donors and ANRs was performed and compared. Test results, organs recovered, and organs transplanted were analyzed.

*Results: The initial time frame was between 1/1/2016 and 3/31/2017 (213 donors; 105 ANRs). The recent data set was between 1/1/2018 and 3/31/2019 (226 donors; 89 ANRs). The recent data set contained 13 additional donors (+6.1%) and 16 fewer ANRs (-15.2%). There were almost equal cases that tested positive for one or both HCV results compared to the previous review (25 vs 26). Of the 25 cases, 17 (5.4% of all cases, 68% of HCV+ cases) compared to 10 previously (3.1% of all cases, 38.5% of HCV+ cases) were recovered donors and 8 (2.5% of all cases, 32.0% of HCV+ cases) compared to 16 (5.0% of all cases, 61.5% of HCV+) were ANRs. Recovered donors positive for HCV increased 70% (10, 17) which yielded 145% increase in organs recovered (20, 49) and a 300% increase in organs transplanted (8, 32) resulting in an increase of OTPD from 0.8 to 1.88. Also noteworthy is a decrease in organs discarded by 42.2%. Organs transplanted in the recent data set comprised of 15 kidneys, 8 livers, 3 hearts and 6 lungs compared to 4 livers and 4 kidneys. The recent data set included two additional HCV+ cases (9 vs 7) where the donors were anti-HCV+/HCV NAT-; of these, both data sets had 5 recovered donors although an increase of 44.4% organs recovered (13 vs 9) and 700% increase of organs transplanted (8 vs 1) and 1.6 vs. 0.2 OTPD. Also, there were 5 DCD donors in both data sets yielding a single organ transplanted (liver).

*Conclusions: The data suggests that a positive HCV result may no longer result in high rates of ANRs, low OTPD and high discard rates. This OPO also suggests that with changing U.S. acceptance practices, more HCV positive organs are being utilized, including thoracic organs transplanted, in the recent data set. Antibody positive, NAT negative results again indicate no better outcomes than donors positive for both tests. Further we conclude that minimal organs are transplanted from DCD donors positive for HCV. We suggest continued review in the acceptance of HCV positive donors as transplant practices change.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Muse CC, Hostetler CA, Squires RA, Orlowski JP. A Follow-Up Over Time to the Impact of Reactive Anti-HCV and HCV NAT [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/a-follow-up-over-time-to-the-impact-of-reactive-anti-hcv-and-hcv-nat/. Accessed May 16, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences